Evaluation of an Intervention to Improve Academic Outcomes for Low-Income Urban Youth through Instruction in Effective Coping Supported by Mentoring Relationships

IA Resilience call reinforcing Europe's strenght in health is sponsored by European Commission — Horizon Europe. Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved scientific understanding, early detection and proactive prevention of diseases through scientific research, continuous monitoring, predictive analytics, and timely alerts, possibly powered by AI algorithms. This preventive approach enables early intervention and significantly reduces risks associated with many illnesses such as viral infections (e.g. epi- and pan demics), cardiovascular diseases, diabetes complications affecting the health of the young and old. • Efficient, scalable, and cost-effective healthcare, demonstrating how ECS-based technologies can streamline clinical workflows, reduce administrative burdens, and improve resource allocation in healthcare systems. This includes automation and intelligent operations management across clinical, diagnostic, and homecare settings, ultimately improving cost-effectiveness and scalability. • Secure and compliant healthcare continuum, including solutions that ensure robust data protection and regulatory compliance (e.g. GDPR), particularly in handling sensitive health data. Projects should adopt privacy-by-design principles and implement secure data handling architectures using localized edge computing, encryption, authentication, and anonymization strategies within both clinical and assisted living environments. • Seamless interoperability across devices, systems, and platforms, addressing the integration of heterogeneous systems across the edge-to-cloud continuum. Solutions should rely on open standards and modular architectures to ensure interoperability, flexibility, and adaptability across various healthcare settings and use cases, fostering a unified European health-tech ecosystem. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space

Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer’s disease and Alzheimer’s disease related dementia (AD/ADRD) and their care partner(s).Distinctive Features:Clinical research and clinical trials are allowed; however, clinical trials solely testing or evaluating pharmacological interventions do not meet the intent of this funding opportunity.Studies utilizing animal models do not meet the intent of the mechanism and are not allowed.Preliminary data are required.Community collaboration is required for research prospectively enrolling human subjects.The AZRP encourages studies to leverage existing cohorts/datasets. Cohorts consisting of individuals 65 years or younger are also encouraged.Career Initiation or Transition (CIT) Partnership Option: The TrCA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet the CIT Partnership Option eligibility requirements at the time of application submission. Funding Opportunity Number: HT942526AZRPTRCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $5.4M total program funding.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Funding Opportunity Number: HT942526PRCRPCTA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $45M total program funding.